Tuesday, March 5, 2019
4:00 PM – 5:00 PM EST
Diagnosis and Treatment of Diffuse Large B Cell Lymphoma (DLBCL)
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). Dr. Michael Crump joined Lymphoma Canada to discuss the current management of DLBCL and recent clinical research advances for this NHL subtype.
Dr. Michael Crump
Hematologist-oncologist, Princess Margaret Cancer Centre
Professor of Medicine, University of Toronto
Dr. Michael Crump is currently a Staff Physician in the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre and a Professor of Medicine at the University of Toronto. Dr. Crump has many additional appointments and professional affiliations, including the following through the National Cancer Institute of Canada: Clinical Trials Group Lymphoma Committee; Co-Chair, Clinical Trials Group Hematology Disease Site; Clinical Trials Group Investigational New Drug Programme Executive Committee Member; Clinical Trials Group Hematology Executive Committee Member. He is also part of the US Lymphoma Steering Committee and the US Hodgkin’s Lymphoma Working Group. He also works with the Ontario Ministry of Health and Long-term Care Committee to Evaluate Drugs (CED), and Cancer Care Ontario, in the Hematology Disease Site Practice Guideline Committee Member and Stem Cell Transplant Steering Committee Member.
Dr. Crump’s research interest is in clinical and translational research in lymphoma, with a focus on stem cell transplantation and development of novel therapies, as well as late effects of treatment. He also has an interest in applied molecular oncology.